463 related articles for article (PubMed ID: 29948107)
1. Radioembolization with
Ho CL; Chen S; Cheung SK; Leung YL; Cheng KC; Wong KN; Wong YH; Leung TWT
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2110-2121. PubMed ID: 29948107
[TBL] [Abstract][Full Text] [Related]
2. Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison.
Gnesin S; Canetti L; Adib S; Cherbuin N; Silva Monteiro M; Bize P; Denys A; Prior JO; Baechler S; Boubaker A
J Nucl Med; 2016 Nov; 57(11):1672-1678. PubMed ID: 27307346
[TBL] [Abstract][Full Text] [Related]
3. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.
Garin E; Lenoir L; Rolland Y; Edeline J; Mesbah H; Laffont S; Porée P; Clément B; Raoul JL; Boucher E
J Nucl Med; 2012 Feb; 53(2):255-63. PubMed ID: 22302962
[TBL] [Abstract][Full Text] [Related]
4. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
Garin E; Rolland Y; Edeline J; Icard N; Lenoir L; Laffont S; Mesbah H; Breton M; Sulpice L; Boudjema K; Rohou T; Raoul JL; Clement B; Boucher E
J Nucl Med; 2015 Mar; 56(3):339-46. PubMed ID: 25678490
[TBL] [Abstract][Full Text] [Related]
5. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology.
Chiesa C; Mira M; Maccauro M; Spreafico C; Romito R; Morosi C; Camerini T; Carrara M; Pellizzari S; Negri A; Aliberti G; Sposito C; Bhoori S; Facciorusso A; Civelli E; Lanocita R; Padovano B; Migliorisi M; De Nile MC; Seregni E; Marchianò A; Crippa F; Mazzaferro V
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1718-1738. PubMed ID: 26112387
[TBL] [Abstract][Full Text] [Related]
6. Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT.
Haste P; Tann M; Persohn S; LaRoche T; Aaron V; Mauxion T; Chauhan N; Dreher MR; Johnson MS
J Vasc Interv Radiol; 2017 May; 28(5):722-730.e1. PubMed ID: 28238581
[TBL] [Abstract][Full Text] [Related]
7. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
8. Significant Value of
Ho CL; Chen S; Cheung SK; Leung TWT
PET Clin; 2019 Oct; 14(4):459-467. PubMed ID: 31472743
[TBL] [Abstract][Full Text] [Related]
9. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept.
Garin E; Lenoir L; Edeline J; Laffont S; Mesbah H; Porée P; Sulpice L; Boudjema K; Mesbah M; Guillygomarc'h A; Quehen E; Pracht M; Raoul JL; Clement B; Rolland Y; Boucher E
Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1057-68. PubMed ID: 23613103
[TBL] [Abstract][Full Text] [Related]
10.
Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
[TBL] [Abstract][Full Text] [Related]
11. Comparative dosimetry between
Jadoul A; Bernard C; Lovinfosse P; Gérard L; Lilet H; Cornet O; Hustinx R
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):828-837. PubMed ID: 31388721
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of imaging
Kunnen B; Dietze MMA; Braat AJAT; Lam MGEH; Viergever MA; de Jong HWAM
Med Phys; 2020 Mar; 47(3):1105-1114. PubMed ID: 31855282
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres.
Garin E; Rolland Y; Laffont S; Edeline J
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):559-75. PubMed ID: 26338177
[TBL] [Abstract][Full Text] [Related]
14. PET-CT post therapy dosimetry in radioembolization with resin
Richetta E; Pasquino M; Poli M; Cutaia C; Valero C; Tabone M; Paradisi BP; Pacilio M; Pellerito RE; Stasi M
Phys Med; 2019 Aug; 64():16-23. PubMed ID: 31515015
[TBL] [Abstract][Full Text] [Related]
15. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization.
Kao YH; Hock Tan AE; Burgmans MC; Irani FG; Khoo LS; Gong Lo RH; Tay KH; Tan BS; Hoe Chow PK; Eng Ng DC; Whatt Goh AS
J Nucl Med; 2012 Apr; 53(4):559-66. PubMed ID: 22343503
[TBL] [Abstract][Full Text] [Related]
16. High quality imaging and dosimetry for yttrium-90 (
Duan H; Khalaf MH; Ferri V; Baratto L; Srinivas SM; Sze DY; Iagaru A
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2426-2436. PubMed ID: 33443618
[TBL] [Abstract][Full Text] [Related]
17. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with
Garin E; Rolland Y; Pracht M; Le Sourd S; Laffont S; Mesbah H; Haumont LA; Lenoir L; Rohou T; Brun V; Edeline J
Liver Int; 2017 Jan; 37(1):101-110. PubMed ID: 27514012
[TBL] [Abstract][Full Text] [Related]
18.
Tabotta F; Gnesin S; Dunet V; Ponti A; Digklia A; Boughdad S; Schaefer N; Prior JO; Villard N; Tsoumakidou G; Denys A; Duran R
Sci Rep; 2023 Aug; 13(1):13118. PubMed ID: 37573346
[TBL] [Abstract][Full Text] [Related]
19. Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization.
Hwang SH; Hong HS; Kim D; Kim GM; Lee HW; Lee M; Kim DY; Park MA; Yun M
Clin Nucl Med; 2022 Jun; 47(6):e437-e443. PubMed ID: 35384891
[TBL] [Abstract][Full Text] [Related]
20. Comparison of absorbed doses to the tumoral and non-tumoral liver in HCC patients undergoing
Noipinit N; Sukprakun C; Siricharoen P; Khamwan K
Ann Nucl Med; 2024 Mar; 38(3):210-218. PubMed ID: 38142421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
